Soleno Therapeutics Inc. (SLNO)
Soleno Therapeutics Statistics
Share Statistics
Soleno Therapeutics has 45.86M shares outstanding. The number of shares has increased by 25.94% in one year.
| Shares Outstanding | 45.86M |
| Shares Change (YoY) | 25.94% |
| Shares Change (QoQ) | 6.35% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 33.47M |
| Failed to Deliver (FTD) Shares | 1.91K |
| FTD / Avg. Volume | 0.2% |
Short Selling Information
The latest short interest is 4.73M, so 10.97% of the outstanding shares have been sold short.
| Short Interest | 4.73M |
| Short % of Shares Out | 10.97% |
| Short % of Float | 14.53% |
| Short Ratio (days to cover) | 8.05 |
Valuation Ratios
The PE ratio is -10.27 and the forward PE ratio is -21.34. Soleno Therapeutics's PEG ratio is -0.12.
| PE Ratio | -10.27 |
| Forward PE | -21.34 |
| PS Ratio | 0 |
| Forward PS | 2.9 |
| PB Ratio | 7.37 |
| P/FCF Ratio | -26.05 |
| PEG Ratio | -0.12 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Soleno Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.68, with a Debt / Equity ratio of 0.01.
| Current Ratio | 15.68 |
| Quick Ratio | 15.68 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | - |
| Debt / FCF | -0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.91M |
| Employee Count | 92 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 76.58% in the last 52 weeks. The beta is -1.69, so Soleno Therapeutics's price volatility has been lower than the market average.
| Beta | -1.69 |
| 52-Week Price Change | 76.58% |
| 50-Day Moving Average | 50.31 |
| 200-Day Moving Average | 49.27 |
| Relative Strength Index (RSI) | 78.59 |
| Average Volume (20 Days) | 942.86K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | 0 |
| Net Income | -175.85M |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | -4.38 |
Balance Sheet
The company has 87.93M in cash and 3M in debt, giving a net cash position of 84.93M.
| Cash & Cash Equivalents | 87.93M |
| Total Debt | 3M |
| Net Cash | 84.93M |
| Retained Earnings | -452.26M |
| Total Assets | 330.97M |
| Working Capital | 275.14M |
Cash Flow
In the last 12 months, operating cash flow was -69.1M and capital expenditures -218K, giving a free cash flow of -69.31M.
| Operating Cash Flow | -69.1M |
| Capital Expenditures | -218K |
| Free Cash Flow | -69.31M |
| FCF Per Share | -1.73 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SLNO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for SLNO is $102, which is 38.3% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $102 |
| Price Target Difference | 38.3% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Aug 26, 2022. It was a backward split with a ratio of 1:15.
| Last Split Date | Aug 26, 2022 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | 19.88 |
| Piotroski F-Score | 2 |